PDF下载 ( 250 KB)
Is nonalcoholic fatty liver disease a complication of diabetes?
-
摘要:
非酒精性脂肪性肝病(NAFLD)虽然是一种肝脏疾病,但越来越受到内分泌学界的重视。糖尿病的代谢状态与NAFLD的病理之间存在复杂的相互作用,促进彼此的发生。在2型糖尿病(T2DM)人群中,脂肪肝伴随率高达57%～80%,合并糖尿病的NAFLD患者可能更容易发生非酒精性脂肪性肝炎(NASH)、肝纤维化等进展性肝病。而NAFLD也促使糖尿病患者糖脂代谢紊乱进一步恶化,以及糖尿病慢性大血管和微血管并发症的发生发展。上述依据支持NASH应被视为T2DM并发症的观点。临床上,一旦T2DM诊断明确,应积极评估NASH或进展性纤维化风险,并积极干预。
Abstract:Although nonalcoholic fatty liver disease( NAFLD) is a liver disease,it has attracted more and more attention among endocrinologists. There are complex interactions between the metabolic status of diabetes and the pathology of NAFLD,and they promote the development of each other. In the population with type 2 diabetes mellitus( T2 DM),the incidence rate of NAFLD is as high as 57%-80%,and NAFLD patients with diabetes are more likely to develop progressive liver diseases such as nonalcoholic steatohepatitis( NASH) and liver fibrosis. NAFLD also leads to the deterioration of glucose and lipid metabolism disorder in diabetes patients,as well as the development and progression of chronic macrovascular and microvascular complications in diabetes. The above evidence supports the view that NASH should be considered a complication of T2 DM. Once a definite diagnosis of T2 DM is made in clinical practice,the risk of NASH or progressive fibrosis should be evaluated and intervention should be given as early as possible.
-
[1] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922. [2] Chinese Society of Endocrinology,Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J].J Clin Hepatol,2018,34(10):2103-2108.(in Chinese)中华医学会内分泌学分会．非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]．临床肝胆病杂志，2018,34(10):2103-2108. [3] YOUNOSSI ZM,GOLABI P,de AVILA L,et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:A systematic review and meta-analysis[J]. J Hepatol,2019,71(4):793-801. [4] BIAN H,ZHU XP,XIA MF,et al. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocr Pract,2020,26(4):444-453. [5] WILD SH,WALKER JJ,MORLING JR,et al. Cardiovascular disease,cancer,and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission[J]. Diabetes Care,2018,41(2):341-347. [6] YOUNOSSI ZM,TAMPI RP,RACILA A,et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U. S.[J]. Diabetes Care,2020,43(2):283-289. [7] TARGHER G,LONARDO A,BYRNE CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus[J]. Nat Rev Endocrinol,2018,14(2):99-114. [8] LUDWIG J,VIGGIANO TR,MCGILL DB,et al. Nonalcoholic steatohepatitis:Mayo Clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc,1980,55(7):434-438. [9] BRIL F,CUSI K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes:A call to action[J]. Diabetes Care,2017,40(3):419-430. [10] YAN HM,GAO X,LIU M,et al. Study of the association between non-alcoholic fatty liver disease and metabolic syndrome[J]. Chin J Diabetes,2006,14(5):326-328.(in Chinese)颜红梅，高鑫，刘蒙，等．非酒精性脂肪肝与代谢综合征关系的研究[J]．中国糖尿病杂志，2006,14(5):326-328. [11] ANSTEE QM,TARGHER G,DAY CP. Progression of NAFLD to diabetes mellitus,cardiovascular disease or cirrhosis[J].Nat Rev Gastroenterol Hepatol,2013,10(6):330-344. [12] YAMAZAKI H,TSUBOYA T,TSUJI K,et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes[J]. Diabetes Care,2015,38(9):1673-1679. [13] CHO HJ,HWANG S,PARK JI,et al. Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus[J]. Gut Liver,2019,13(4):440-449. [14] SIMEONE JC,BAE JP,HOOGWERF BJ,et al. Clinical course of nonalcoholic fatty liver disease:An assessment of severity,progression,and outcomes[J]. Clin Epidemiol,2017,9:679-688. [15] PANG Y,KARTSONAKI C,TURNBULL I,et al. Diabetes,plasma glucose,and incidence of fatty liver,cirrhosis,and liver cancer:A prospective study of 0. 5 million people[J].Hepatology,2018,68(4):1308-1318. [16] ALLER de la FUENTE R,MORA CUADRADO N,TAFUR C,et al.Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes[J]. Endocrinol Diabetes Nutr,2018,65(6):354-360. [17] LEITE NC,VILLELA-NOGUEIRA CA,PANNAIN VL,et al.Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes:Prevalences and correlated factors[J]. Liver Int,2011,31(5):700-706. [18] ADAMS LA,SANDERSON S,LINDOR KD,et al. The histological course of nonalcoholic fatty liver disease:A longitudinal study of 103 patients with sequential liver biopsies[J]. J Hepatol,2005,42(1):132-138. [19] SMITH BW,ADAMS LA. Nonalcoholic fatty liver disease and diabetes mellitus:Pathogenesis and treatment[J]. Nat Rev Endocrinol,2011,7(8):456-465. [20] LOOMBA R,ABRAHAM M,UNALP A,et al. Association between diabetes,family history of diabetes,and risk of nonalcoholic steatohepatitis and fibrosis[J]. Hepatology,2012,56(3):943-951. [21] WANG C,WANG X,GONG G,et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus:A systematic review and meta-analysis of cohort studies[J]. Int J Cancer,2012,130(7):1639-1648. [22] MITTAL S,SADA YH,EL-SERAG HB,et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population[J]. Clin Gastroenterol Hepatol,2015,13(3):594-601. e1. [23] AMARAPURKAR DN,PATEL ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values[J]. Trop Gastroenterol,2004,25(3):130-134. [24] BRIL F,MCPHAUL MJ,CAULFIELD MP,et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes[J]. Diabetes Care,2020,43(2):290-297. [25] LOMONACO R,BRIL F,PORTILLO-SANCHEZ P,et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes[J]. Diabetes Care,2016,39(4):632-638. [26] TARGHER G,LONARDO A,BYRNE CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus[J]. Nat Rev Endocrinol,2018,14(2):99-114. [27] LOMBARDI R,AIRAGHI L,TARGHER G,et al. Liver fibrosis by FibroScanindependently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes[J]. Liver Int,2020,40(2):347-354. [28] TARGHER G,BYRNE CD,LONARDO A,et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A meta-analysis[J]. J Hepatol,2016,65(3):589-600. [29] TARGHER G,CHONCHOL M,BERTOLINI L,et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease[J]. J Am Soc Nephrol,2008,19(8):1564-1570. [30] WILLIAMS KH,BURNS K,CONSTANTINO M,et al. An association of large-fibre peripheral nerve dysfunction with noninvasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes[J]. J Diabetes Complications,2015,29(8):1240-1247. [31] CUSI K. A diabetologist's perspective of non-alcoholic steatohepatitis(NASH):Knowledge gaps and future directions[J].Liver Int,2020,40(Suppl 1):82-88. [32] BRIL F,CUSI K. Nonalcoholic fatty liver disease:The new complication of type 2 diabetes mellitus[J]. Endocrinol Metab Clin North Am,2016,45(4):765-781. [33] CUSI K. Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes[J]. Diabetes Care,2020,43(2):275-279. -
本文二维码
计量
- 文章访问数: 599
- HTML全文浏览量: 40
- PDF下载量: 136
- 被引次数: 0
下载:
